What happened
Pathos AI Inc. has raised $237 million in funding at a $3 billion valuation, led by pharmaceutical giant Bristol Myers Squibb Co. The funding will be used to finance the company's drug development efforts, including its JSKN016 program, which aims to develop a cancer therapy based on an antibody-drug conjugate.
Pathos AI Inc. has raised $237 million in funding at a $3 billion valuation, led by pharmaceutical giant Bristol Myers Squibb Co.
The funding will be used to finance the company's drug development efforts, including its JSKN016 program, which aims to develop a cancer therapy based on an antibody-drug conjugate.
The company's AI platform, Foundry, uses AI agents to pinpoint the most promising molecules and identify the patients who could benefit the most from each therapy.
Pathos AI Inc. will also use the funding to finance three other drug programs, including a collaboration with AstraZeneca.
Source details: siliconangle.com ↗
Why it matters
The funding will help Pathos AI Inc. to accelerate its drug development efforts and improve the probability of success in drug development. The company's AI platform, Foundry, uses AI agents to pinpoint the most promising molecules and identify the patients who could benefit the most from each therapy.
The funding will help Pathos AI Inc. to accelerate its drug development efforts and improve the probability of success in drug development.
The company's AI platform, Foundry, has fundamentally accelerated its ability to identify highly promising clinical assets and integrate them into its .
The funding will also help Pathos AI Inc. to finance its collaborations with other companies, including AstraZeneca and Tempus AI Inc.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
crm_get_transaction(id='4092').A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
What to watch next
The company's JSKN016 program, which aims to develop a cancer therapy based on an antibody-drug conjugate, is a key priority for Pathos AI Inc. The company will also use the funding to finance three other drug programs, including a collaboration with AstraZeneca.
The company's JSKN016 program, which aims to develop a cancer therapy based on an antibody-drug conjugate, is a key priority for Pathos AI Inc.
The company will also use the funding to finance three other drug programs, including a collaboration with AstraZeneca.
The company's AI platform, Foundry, will continue to play a key role in its drug development efforts.
The company will also use the funding to license anonymized data collected from patients with neurological conditions from Tempus AI Inc.